This is the authors' abstract. We don't add key points for this paper.
Rapid drug discovery is a pressing need in the pharmaceutical industry. As new target proteins are proposed for therapeutic intervention, the methods of random screening or rational drug design may not be adequate to the challenge. SELEX1(1) -derived oligonucleotides, possessing shapes that interact with target molecules, may provide a surprising alternative to other ligand discovery technologies. In addition, the technology leads to a novel research idea that may enrich our understanding of the mechanisms by which cells and organisms integrate their metabolic activities.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Larry Gold (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: